WHO RSV Roadshow Web Event 5

On Wednesday 15th of January we organised in collaboration with WHO and PATH the fifth Web Event “The RSV Immunisation Pipeline to Global Policy and Programmatic Use“.

What are the pathways to RSV prevention access and use in low- and middle-income markets?

We will discuss policy consideration on the pathway to global RSV prevention for infants and young children, including vaccine introduction timeline drivers; global policy and WHO prequalification processes; immunization financing; and country policymaking. We will also discuss new RSV immunization product implementation considerations and adaptations that may be needed to introduce and scale up delivery.

Recording Available

Catch up on our recent web event, ‘The RSV Immunisation Pipeline to Global Policy and Programmatic Use’. Watch the full recording below to gain valuable insights from leading experts in the field.

Our host, speakers and expert reflection

Dr. Emmanuel Mugisha

Vaccinologist at PATH

Dr. Emmanuel Mugisha is a vaccinologist with close to 30 years of experience in research and public health programing. Has vast experience in clinical vaccine trials, pilot programs as well as new vaccine introduction across the African region and Asian regions. Currently, Dr. Emmanuel serves as Global Director, TyVAC (Typhoid Vaccine Acceleration Consortium) Project and Senior Advisor on vaccines and immunizations, where he provides overall leadership on country introductions of Typhoid vaccine in selected countries in Africa and Asia. Additionally, he provides technical support on other vaccines and immunization programs in the African and Asian regions.

DrPH, MSc Erin Sparrow

Technical Officer, WHO

Erin Sparrow is a public health expert with 18 years of experience working at the World Health Organization (WHO). She specializes in vaccine development and infectious diseases and currently serves in the Product and Delivery Research unit (PDR) within WHO’s Department of Immunization, Vaccines, and Biologicals (IVB). In her current role, she focuses on advancing the development of priority products and innovative technologies to optimize the impact of vaccines and monoclonal antibodies. Since 2017, Erin has worked on advancing the development of RSV immunization products and more recently in coordinating the development of WHO policy recommendations for RSV through the Strategic Advisory Group of Experts (SAGE).

PhD, MSc Jessica Fleming

Senior Research Scientist and Maternal Immunization Delivery Lead

Jessica Fleming is an infectious disease epidemiologist and senior research scientist working in PATH’s Center for Vaccine Introduction and Access, based in Seattle, Washington. Over the last 25 years, Dr. Fleming’s work has spanned the full continuum of product development—from ensuring public health technologies are designed appropriately for their intended use, to conducting research to quantify their impact. Dr. Fleming began her career in maternal immunization at Unicef, working with local stakeholders to organize maternal tetanus vaccination campaigns in complex emergencies and humanitarian settings. As PATH’s maternal immunization delivery lead, her work includes generating evidence and working closely with partners to disseminate information to support informed policy recommendations, with a focus on the new maternal RSV vaccine.

Dr. Eve Nakabembe

Senior Obstetrician gynecologist/Maternal vaccinologist at Makerere University, School of Medicine

Dr Eve Nakabembe is a senior Obstetrician/ Gynecologist, clinical researcher and academic based at Makerere University School of Medicine. She is a clinician at Mulago specialized women and neonatal hospital in Kampala, Uganda. Eve has more than 20 years’ experience working in Sub Saharan Africa on different programs to improve maternal,newborn and child and health. Eve’s research work is focused on maternal vaccine use in low- and middle-income countries and their effectiveness in special populations like pregnant women living with HIV. Her research work explores the safety and immunogenicity of new vaccines including RSV and GBS, vaccine demand, cost effectiveness and the true burden of disease for vaccine preventable pathogens in pregnant women and infants.

Upcoming Events

Web Events Program 2024 – 2025